EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Comprehensive Review

Lukas Delasos iD, Khaled A Hassan

JCO Oncology Practice · 2026

DOI: 10.1200/op-25-01061 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Oncology Practice, 2026. Verfasst von Lukas Delasos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Taussig Cancer Center, Cleveland, OH. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape of non–small cell lung cancer (NSCLC) has advanced considerably in the past two decades, driven largely by molecular profiling and the development of targeted therapies. Among oncogenic drivers, mutations in the epidermal growth factor receptor (EGFR) have proven to be particularly significant, with the introduction of tyrosine kinase inhibitors (TKIs) revolutionizing management. While first- and second-generation EGFR TKIs improved disease-free survival (DFS), they failed to confer overall survival (OS) benefit in the adjuvant setting. Osimertinib, a third-generation EGFR TKI with superior potency, CNS penetration, and tolerability, has emerged as the standard of care for nearly all stages of EGFR -mutated NSCLC. The phase III ADAURA trial demonstrated that adjuvant osimertinib significantly prolonged DFS and OS in patients with stage IB-IIIA, resected EGFR exon 19 deletion, or L858R-mutated NSCLC. Similarly, the phase III LAURA trial established osimertinib as consolidation therapy after chemoradiotherapy in unresectable stage III EGFR -mutated NSCLC, yielding a dramatic progression-free survival benefit and reduced CNS relapse rates. As osimertinib use expands, clinicians must remain vigilant regarding toxicity, including rash, diarrhea, cytopenias, and rarer but serious risks such as interstitial lung disease and cardiotoxicity. Optimal treatment duration, the role of adjuvant chemotherapy, and surveillance strategies remain subjects of active investigation. Emerging technologies, such as circulating tumor DNA for minimal residual disease detection and radiomic analyses, may refine patient selection and duration of therapy. Future directions include perioperative use of osimertinib, as explored in the ongoing NeoADAURA trial, and extension of the adjuvant TKI paradigm to other oncogenic drivers such as ALK , ROS1 , and RET . Collectively, these advances herald a new era of precision oncology in NSCLC, where targeted therapies are reshaping curative-intent treatment strategies for oncogene-driven disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsHumansErbB ReceptorsMutationPyrimidinesAcrylamides

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanPyrimidinesAcrylamides

Autor:innen und Institutionen

  • Cleveland Clinic Taussig Cancer Center, Cleveland, OH.

ORCID-Profile: Lukas Delasos

Zitieren

APA

Delasos, L., & Hassan, K. A. (2026). Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Comprehensive Review. JCO Oncology Practice. https://doi.org/10.1200/op-25-01061

Vancouver

Delasos L, Hassan KA. Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Comprehensive Review. JCO Oncology Practice. 2026. doi:10.1200/op-25-01061

BibTeX
@article{Delasos2026,
  author = {Delasos, Lukas and Hassan, Khaled A},
  title = {Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Comprehensive Review},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-01061}
}
Kostenlos starten →